Trial Profile
Phase II study of Proteasome inhibitor Bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma unspecified PTCLU and cutaneous T-cell lymphoma CTCL.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 May 2011
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 25 May 2011 New trial record